BUZZ-J.P. Morgan initiates coverage of <a href="https://laohu8.com/S/AKTS">Aktis Oncology</a> with 'overweight' rating** J.P. Morgan initiates coverage of Aktis Oncology AKTS.O with "overweight" rating; sets PT of $30
** Brokerage lauds cancer drug developer's platform for developing radiopharmaceutical therapies, which are a novel means of delivering targeted radiation for cancer
** "We see the RPT modality taking off in the coming years and see Aktis entering at a sweet spot where it can both leverage past learnings in the space while also being early enough to be positioned to develop first-in-class products in a relatively open field," says JPM
** Including session's move, AKTS is down 20.9% since its debut on January 9
(Reporting by Pragyan Kalita in Bengaluru)
((Pragyan.Kalita@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments